Syphilis Testing Market Size & Growth Forecast 2027–2036, By Segments (Location of Testing, Technology), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
Syphilis Testing Market size was estimated at USD 1.57 billion in 2026 and is projected to grow at a 5.51% CAGR from 2027 to 2036, attaining USD 2.68 billion by 2036. The industry revenue for 2027 is assessed at USD 1.64 billion.
Get more details on this report
Request Free Sample ReportSyphilis Testing Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 42.58% revenue share in 2026, benefiting from established laboratory infrastructure, accessible diagnostic services, and screening initiatives focused on early detection and maternal health.
- Asia Pacific is growing fastest as healthcare infrastructure improves, diagnostic access expands, and public health and maternal healthcare programs increasingly emphasize early detection and preventive screening.
Segment Momentum
- Laboratory testing held 61.31% of the market in 2026, supported by established diagnostic infrastructure, trained personnel, quality-controlled workflows, and its integration into routine screening and confirmatory testing programs.
- Point-of-care testing is growing fastest because it enables diagnosis closer to patients, reduces reliance on centralized laboratories, and supports timely clinical decisions in community programs, primary care facilities, and resource-limited settings.
Market Expansion Drivers
- Rising prevalence of sexually transmitted infections and demand for early diagnosis.
- Technological advancements in rapid syphilis test kits.
- Government programs promoting STI screening and testing.
Leading Market Participants
- Major players in the syphilis testing market include Roche (Switzerland), Abbott (USA), Siemens Healthineers (Germany), Bio-Rad Laboratories (USA), Danaher (USA), DiaSorin (Italy), Ortho Clinical Diagnostics (USA), Sysmex (Japan), Randox Laboratories (UK), Mindray (China).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 1.57 billion
- 2027 Estimated Market Size: USD 1.64 billion
- Projected Market Size: USD 2.68 billion by 2036
- Growth Forecast: 5.51% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Location of Testing (Laboratory Testing) | Technology (Immunoassay)
- Emerging Opportunity Segment: Location of Testing (Point of Care Testing) | Technology (Molecular Diagnostics)
Market Growth Drivers and Industry Trends
Rising prevalence of sexually transmitted infections and demand for early diagnosis
The growing burden of sexually transmitted infections is increasing the need for accessible and timely syphilis screening and diagnosis. Early detection enables appropriate clinical management and helps reduce the risk of transmission, particularly among populations with elevated exposure risks. Greater awareness of sexual health and the integration of STI screening into broader healthcare services are supporting sustained demand for reliable syphilis testing solutions.
Technological advancements in rapid syphilis test kits
Advancements in rapid diagnostic technologies are improving the convenience, accessibility, and efficiency of syphilis testing. Development of easy-to-use testing formats, faster result availability, and improved diagnostic performance is supporting broader adoption in decentralized healthcare settings. Increasing demand for point-of-care testing is further encouraging the development of solutions that can facilitate timely screening and clinical decision-making outside conventional laboratory environments.
Government programs promoting STI screening and testing
Government-led initiatives focused on sexually transmitted infection prevention and screening are strengthening demand for syphilis testing services. Public health programs increasingly emphasize early diagnosis, routine screening of at-risk populations, maternal health protection, and prevention of disease transmission. Expansion of community-based testing and integration of STI screening into public healthcare programs are improving access to diagnostic services and supporting broader utilization of syphilis tests.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of sexually transmitted infections and demand for early diagnosis | 5% | Short term (≤ 2 yrs) | North America; Europe | Medium | Fast |
| Technological advancements in rapid syphilis test kits | 4% | Medium term (2–5 yrs) | Asia Pacific; North America | Low | Moderate |
| Government programs promoting STI screening and testing | 3.5% | Long term (5+ yrs) | Europe; North America; Spillover: MEA | High | Moderate |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
The North America syphilis testing market accounted for the largest revenue share of 42.58% in 2026, supported by established healthcare systems, widespread availability of diagnostic services, and increasing emphasis on sexually transmitted infection screening. Public health programs and clinical screening practices are encouraging earlier detection and treatment, particularly among populations with elevated risk of infection. The region benefits from well-developed laboratory infrastructure and increasing adoption of rapid and molecular diagnostic technologies that can improve testing accessibility and turnaround times. Growing awareness of sexually transmitted infections is also supporting greater participation in screening programs across healthcare settings. In addition, increased focus on maternal and prenatal health is strengthening the role of syphilis testing in routine healthcare, while improvements in diagnostic capabilities are supporting broader screening and disease management efforts.
Asia Pacific (Fastest-Growing Region)
The Asia Pacific syphilis testing market is witnessing the fastest growth, driven by improving healthcare infrastructure, increasing awareness of sexually transmitted infections, and expanding access to diagnostic services. Governments and healthcare providers are placing greater emphasis on early detection and prevention, supporting the integration of syphilis screening into broader public health and maternal healthcare programs. The expansion of hospitals, laboratories, and community healthcare services is improving access to diagnostic testing, particularly in emerging markets. Advances in rapid testing technologies are also helping healthcare providers overcome accessibility and turnaround challenges in areas with limited laboratory resources. Furthermore, growing awareness of preventive healthcare and increasing attention to reproductive and maternal health are encouraging broader adoption of syphilis testing across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
United States 🇺🇸
Screening IntegrationThe U.S. market is shaped by broader STI screening protocols, decentralized testing, and integration of syphilis diagnostics into sexual health and primary-care workflows. Priorities include rapid and laboratory-based testing access, automated result reporting, and targeted screening among populations with elevated transmission risk.
Germany 🇩🇪
Laboratory DiagnosticsGermany’s syphilis testing demand centers on established laboratory infrastructure and standardized diagnostic pathways across specialist and public-health settings. Market priorities include reliable confirmatory testing, efficient laboratory workflows, and stronger linkage between screening, surveillance, and treatment services.
Japan 🇯🇵
Clinical Screening ExpansionJapan’s market emphasizes dependable laboratory diagnostics alongside greater attention to timely STI detection. Priorities include expanding convenient screening access, improving clinician awareness of changing testing needs, and supporting diagnostic workflows that enable earlier identification and treatment of syphilis cases.
South Korea 🇰🇷
Accessible STI TestingSouth Korea’s syphilis testing market is supported by hospital-based diagnostics and increasing demand for accessible sexual-health services. Commercial priorities include rapid testing options, streamlined laboratory turnaround, and discreet testing pathways that can improve patient engagement and facilitate earlier clinical intervention.
France 🇫🇷
Public-Health ScreeningFrance’s market is closely connected to public-health screening and sexually transmitted infection prevention programs. Priorities include accessible testing through healthcare and community channels, dependable confirmatory diagnostics, and stronger integration of screening results with prevention, partner management, and treatment pathways.
Italy 🇮🇹
Diagnostic Access ImprovementItaly’s syphilis testing landscape reflects the need to maintain reliable diagnostic capacity across hospitals, laboratories, and sexual-health services. Market priorities include improving access to timely testing, simplifying diagnostic workflows, and strengthening coordination between laboratory confirmation and follow-up care.
Syphilis Testing Market Share (%), by Location of Testing, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportLocation of Testing Segment Analysis: Laboratory Testing (Largest Segment) vs Point of Care Testing (Fastest-Growing Segment)
The laboratory testing segment accounted for a 61.31% share of the location of testing segment in 2026, supported by the established role of centralized laboratories in providing structured diagnostic workflows, trained personnel, and access to established testing infrastructure. Laboratory-based syphilis testing can support comprehensive diagnostic processes and quality-controlled procedures, making it an important option for hospitals, diagnostic centers, and public health programs. The continued use of laboratory facilities for infectious disease screening, confirmatory testing, and routine diagnostic services sustains demand for laboratory-based approaches. Established healthcare infrastructure and the integration of syphilis testing into broader diagnostic workflows further reinforce the segment's leading position.
Point of care testing is the fastest-growing location of testing segment, driven by the increasing need for rapid and accessible diagnosis in settings where conventional laboratory infrastructure may be limited or where immediate clinical decisions are important. Point-of-care testing enables screening and diagnosis closer to the patient, reducing dependence on centralized facilities and potentially shortening the time between testing and treatment decisions. Its suitability for community health programs, primary care facilities, outreach initiatives, and resource-limited settings is supporting broader adoption. Increasing efforts to expand sexually transmitted infection screening and improve access to timely diagnosis are further encouraging the use of point-of-care testing, particularly among populations that may face geographic, logistical, or healthcare-access barriers.
Technology Segment Analysis: Immunoassay (Largest Segment) vs Molecular Diagnostics (Fastest-Growing Segment)
The immunoassay segment accounted for a 46.59% share of the technology segment in 2026, reflecting the established use of immunoassay-based approaches in syphilis screening and diagnostic workflows. These technologies are widely suited to laboratory environments and can support efficient screening of large patient populations, making them valuable for hospitals, diagnostic laboratories, and public health testing programs. Their established infrastructure, familiarity among healthcare professionals, and integration into routine infectious disease testing workflows contribute to continued adoption. The need for scalable screening solutions and expanded testing coverage is expected to sustain the role of immunoassay technology across established diagnostic settings.
Molecular diagnostics are expected to experience the fastest growth in the technology segment, supported by increasing interest in advanced testing approaches that can provide greater analytical specificity and support more sophisticated infectious disease detection. Advances in molecular testing are improving the accessibility and efficiency of diagnostic workflows while expanding opportunities for more targeted detection. Growing emphasis on early diagnosis, improved disease surveillance, and the development of increasingly advanced diagnostic infrastructure is supporting adoption of molecular technologies. As healthcare providers and laboratories seek enhanced diagnostic capabilities and more precise testing solutions, molecular diagnostics are gaining momentum in syphilis testing applications.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Location of Testing | Laboratory Testing, Point of Care Testing | Laboratory Testing | Point of Care Testing |
| Technology | Molecular Diagnostics, Immunoassay, Others | Immunoassay | Molecular Diagnostics |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Analyst Perspective:
The competitive architecture of the syphilis diagnostic market is defined by a dual demand for high-throughput central laboratory efficiency and immediate point-of-care accessibility. High-volume laboratories favor automated chemiluminescent immunoassays and multiplex treponemal panels that streamline testing for multiple pathogens, though these must be coupled with quantitative non-treponemal antibody titers to effectively differentiate active disease from prior infection and monitor therapeutic response. Conversely, market growth outside traditional laboratory walls relies on rapid point-of-care formats that deliver reliable results during a single patient encounter, enabling timely clinical intervention in decentralized, antenatal, or resource-constrained settings.
Key companies in the syphilis testing market:
- Roche (Switzerland)
- Abbott (USA)
- Siemens Healthineers (Germany)
- Bio-Rad Laboratories (USA)
- Danaher (USA)
- DiaSorin (Italy)
- Ortho Clinical Diagnostics (USA)
- Sysmex (Japan)
- Randox Laboratories (UK)
- Mindray (China)
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Roche (Switzerland) | |||||||
| Abbott (USA) | |||||||
| Siemens Healthineers (Germany) | |||||||
| Bio-Rad Laboratories (USA) | |||||||
| Danaher (USA) | |||||||
| DiaSorin (Italy) | |||||||
| Ortho Clinical Diagnostics (USA) | |||||||
| Sysmex (Japan) | |||||||
| Randox Laboratories (UK) | |||||||
| Mindray (China) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Abbott | July 2025 | Abbott launched a WHO-approved triple test kit for African mothers to screen for HIV/AIDS, hepatitis B, and syphilis. This point-of-care solution expands integrated maternal screening capabilities and broadens access to infectious-disease diagnostics for pregnant women. |
| NOWDiagnostics, Inc. | August 2024 | The U.S. FDA authorized the First To Know Syphilis Test by NOWDiagnostics, Inc. via the De Novo pathway, marking the first over-the-counter, at-home syphilis antibody test delivering finger-stick results in 15 minutes. |
| NOWDx | January 2024 | NOWDx submitted a De Novo Classification Request to the U.S. FDA for its First to Know at-home syphilis test, marking an early step toward expanding consumer-accessible, over-the-counter decentralized screening options. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Syphilis Testing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Patient Type | Pregnant Women, General Adult Population, High-Risk Populations, Newborns |
| Screening Program | Prenatal Screening, Sexual Health Screening, Blood Donor Screening, Targeted Public Health Screening |
| Customer Setting | Public Health Clinics, Private Diagnostic Laboratories, Hospitals & Clinics, Community & Outreach Centers |
Syphilis Testing Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Screening Program Effectiveness |
|
| High-Risk Population Testing Pathways |
|
| Elimination Strategy Readiness |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
What is the market size of the syphilis testing market?
What is the projected value of the syphilis testing industry by 2036?
How is the emphasis on early STI diagnosis influencing demand for syphilis testing?
How are rapid testing technologies and public screening programs expanding syphilis testing access?
Why does laboratory testing account for the largest share of the syphilis testing market?
How is point-of-care testing expanding opportunities in the syphilis testing market?
What supports North America's leadership in the syphilis testing market?
Why is Asia Pacific becoming a key growth market for syphilis testing?
Which companies dominate the syphilis testing landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook